Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Silverfleet Capital on its investment in Collectia
Mandate

Vinge advises Silverfleet Capital on its investment in Collectia

February 21, 2020 M&A

Silverfleet Capital, the European private equity firm, has acquired a majority stake in Collectia A/S, (“Collectia” or the “Company”), a credit management services provider based in Denmark.

Collectia is a fast-growing debt collection and debt purchase business operating in Denmark with a presence in Sweden, Norway and Germany. The Company employs over 175 staff and serves approximately 13,000 corporate customers across over 600,000 active cases.
 
The Vinge team included partner Christina Kokko and associates Anna Thoms and Vilhelm Rondahl. Partner Emma Stuart-Beck and associate Mikaela Lang advised on regulatory aspects of the transaction. Partner Louise Brorson Salomon and associates Ludwig Wettergren and Hannes Pettersson advised on financial aspects of the transaction.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025